Orchestra BioMed increases CEO base salary 4%, President/COO 10%; updates bonus plan and RSU vesting.

Orchestra BioMed Holdings, Inc.

CEO David Hochman base salary raised 4%; target bonus increased from 80% to 100% of base for 2026.
President/COO Mark Sherman base salary raised 10%; target bonus increased from 80% to 90% of base.
2026 bonus plan ties to clinical trial enrollment milestones for BACKBEAT and Virtue SAB studies.
RSU awards now vest 25% at 18, 24, 30, and 36 months; prior schedule changed.
CFO Andrew Taylor's bonus can be adjusted -45% to +0% based on individual performance objectives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.